340B Drug Pricing Program
The AHA today responded to a report that is the “latest in a series of attempts to misrepresent” the 340B Drug Pricing Program and the benefits it helps bring to poor patients and vulnerable communities.
A report paid for by a group backed by the pharmaceutical industry is the latest in a series of attempts to misrepresent a program that has a proven track record of helping poor patients and vulnerable communities.
The AHA late Friday filed a friend-of-the-court brief in support of the Department of Health and Human Services in a federal lawsuit seeking to exclude all drugs with an “orphan” designation from an HHS interpretive rule expanding the 340B Drug Pricing Program to rural and cancer hospitals under…
A new report ;by the Berkley Research Group (BRG) is the latest attempt by the pharmaceutical industry to disparage a program with a proven track record of helping poor patients and vulnerable communities.
The 340B program accounts for only two percent of the $325 billion in annual drug purchases made in the U.S., or roughly $6.5 billion. Hospitals participating in the 340B program provided $28.4 billion in uncompensated care in 2012; in other words, four times the drug purchase amount.
Yesterday, the Health Resources and Services Administration (HRSA) published its final rule clarifying the Patient Protection and Affordable Care Act (ACA) provision that excludes orphan drugs for purchase under the 340B drug pricing program
Submit Letters to HRSA Outlining Challenges with 340B GPO Notice -- AHA model letter can guide your comments